Past exam of the biochemistry and Molecular Biology course of the University of Cambridge / 2024 / Paper 1 / Section D

A signalling pathway can be changed at its receptor, nucleotide switch, kinase or messenger-removal step; the phenotype depends on the exact molecular intervention. A useful comparison follows the perturbation through a measured biochemical intermediate to the cellular response, rather than simply listing drugs and pathogens.

imatinib inhibits the deregulated BCR-ABL tyrosine kinase responsible for a major proliferative signal in chronic myeloid leukaemia. Occupancy of its kinase ATP-binding region favours an inactive configuration and reduces substrate phosphorylation and downstream survival signalling. Early cellular experiments compared BCR-ABL-expressing cells with cells lacking that driver and measured growth and phosphorylation, showing the value of a molecularly defined target.^[ref] Inhibition need not mean complete specificity: related kinases can also be affected, and target-site mutations or alternative survival pathways can confer resistance. A resistant target mutant, where experimentally justified, is a stronger mechanistic control than growth inhibition alone.

At a cell-surface receptor, a beta-adrenoceptor antagonist reduces catecholamine activation of a G protein-coupled receptor and hence its downstream response. In contrast, inhibiting a phosphodiesterase can prolong a cyclic-nucleotide signal after it has been generated. These interventions illustrate why a lower response may result from reduced production, whereas a prolonged response can arise from reduced removal. Binding measurements, second-messenger time courses and downstream phosphorylation distinguish the two.

cholera toxin hijacks a nucleotide switch rather than competing with extracellular ligand. Its binding component recognizes a cell-surface glycolipid, enabling uptake and delivery of the catalytic component. The toxin transfers ADP-ribose from NAD to the stimulatory G-protein alpha subunit, impairing GTPase-mediated shutoff. Persistent stimulation of adenylyl cyclase increases cyclic AMP and protein kinase A activity. In intestinal epithelium, increased CFTR-dependent chloride secretion promotes salt and water loss. Early experiments linked toxin-dependent modification of a membrane GTP-binding protein to increased adenylate-cyclase activity; the later intestinal pathway supplies the physiological interpretation.^[ref]

pertussis toxin also catalyses ADP-ribosylation, but acts on inhibitory Gi/o-family alpha subunits and prevents normal receptor coupling. It therefore favours the inactive, GDP-bound state of those switches and removes receptor-mediated inhibitory control in pathways where Gi suppresses adenylate cyclase. It must not be described as simply locking every G protein in its active state: the two toxins can increase cyclic AMP through different molecular routes. Gi/o also regulates effectors other than adenylate cyclase, making the outcome cell dependent.

Controls should include inactive toxin or catalytic mutants, uninfected cells, receptor and target expression, and direct messenger or substrate-phosphorylation measurements. Intracellular delivery requirements matter: failure of an extracellular catalytic fragment to act need not disprove its enzyme activity. Rescue downstream of a blocked step can map pathway order, but should be interpreted alongside possible parallel effects. Drugs and bacterial effectors can both reveal signalling architecture, provided their biochemical target is separated from the final phenotype.

Selective destruction makes key transitions depend on rebuilding proteins, rather than merely reversing their phosphorylation state. ubiquitin-proteasome system supplies this directionality while cyclin-dependent kinases and phosphatases provide more rapidly reversible regulation. An ubiquitin-activating enzyme uses ATP to activate ubiquitin; transfer through an ubiquitin-conjugating enzyme and recognition by an ubiquitin ligase directs substrate modification. Suitable polyubiquitin chains target proteins to the proteasome for unfolding and destruction. Substrate recognition, rather than a general increase in protein breakdown, gives temporal specificity.

At the G1/S transition, an SCF ubiquitin ligase can recognize a phosphorylated inhibitor of a cyclin-dependent kinase. In budding yeast, multisite phosphorylation of Sic1 promotes its destruction, releasing S-phase kinase activity. This links a threshold of previous kinase activity to removal of an inhibitor. Different SCF substrate receptors recognize different proteins, and phosphorylation-dependent recognition is important for many, but not every, SCF target. Destruction reinforces entry into the new state while the kinase network supplies additional feedback.

The anaphase-promoting complex controls a particularly decisive transition. Its Cdc20-associated form is restrained by the spindle checkpoint until chromosome attachment conditions permit progression. Ubiquitination and destruction of securin release separase, which cleaves the cohesin component that holds sister chromatids together. Chromatid separation cannot be undone by putting the phosphate groups back onto an intact securin molecule, because that molecule has been degraded and the cohesion linkage has been cleaved. The combination of selective proteolysis and substrate cleavage explains why a brief regulatory transition commits the cell to anaphase.

Destruction of cyclin B lowers CDK1 activity and enables mitotic exit. Nondegradable cyclin blocked inactivation of maturation-promoting activity and exit from mitosis in frog experimental systems, directly testing necessity of cyclin destruction rather than merely observing a correlation.^[ref] The Cdh1-associated anaphase-promoting complex helps keep mitotic cyclins low through late mitosis and G1, creating an interval suitable for replication licensing. In animal cells, destruction of geminin also permits Cdt1 to support licensing. Subsequent kinase activation and licensing-factor regulation help prevent rereplication before the next cycle.

The mechanism is irreversible on the timescale of the transition, not an assertion that the cell can never make cyclin or securin again. ATP-dependent ubiquitin activation and proteasomal processing occur in an open, energy-consuming system; fresh gene expression later restores substrates under a different regulatory state. Conversely, ubiquitination alone is not synonymous with degradation: chain type and context can give other signals. Tests should compare normal and degron-mutant substrates at similar expression levels, monitor actual protein loss and kinase activity, and distinguish checkpoint arrest from failure of destruction itself. Proteolysis commits the cell by removing selected regulators, while checkpoint and feedback circuits determine when that commitment occurs.

p53 prevents stressed or potentially dangerous cells from expanding by coordinating repair, arrest, senescence and, when appropriate, cell death. The normal p53 protein is a sequence-specific transcription factor encoded by TP53. Its low unstressed abundance is maintained partly by MDM2-dependent ubiquitination and degradation. DNA damage, oncogene-associated stress and other perturbations can stabilize and activate it through signalling that modifies p53, its regulators and their interactions. p53 also induces MDM2, forming a negative-feedback loop that allows recovery when the initiating stress resolves.

One outcome is reversible cell-cycle arrest. p53 induces p21, a cyclin-dependent-kinase inhibitor, reducing kinase activity and helping retain RB control over E2F-dependent cell-cycle entry. This gives cells time to repair damage before DNA replication or division distributes errors. A pause itself is not DNA repair: repair enzymes must still remove lesions, and the cell must reassess whether proliferation can safely resume. Time-resolved measurements of p53, p21 and cell-cycle progression therefore distinguish a protective transient response from a permanent arrest.

Severe or persistent stress can favour apoptosis. p53-dependent expression of PUMA, NOXA and BAX can shift the balance of BCL-2-family activities towards mitochondrial outer-membrane permeabilization and caspase activation. Removing a damaged cell prevents transmission of its mutations, but costs that cell to the tissue. Alternatively, cellular senescence produces a durable arrest that blocks immediate clonal expansion. The associated secretory phenotype can recruit immune responses, yet can also alter neighbouring tissue in harmful ways. Neither apoptosis nor senescence is an inevitable consequence of every increase in p53; duration, dose, cell type and survival signals shape the outcome.

p53 also coordinates aspects of metabolism, redox control and maintenance of genome integrity. These functions can support survival during manageable stress and suppress conditions that favour transformation. It would therefore be misleading to identify normal p53 solely as a death trigger or to assume that all its anticancer effects require an acute DNA-damage checkpoint. The barrier is layered: limiting mutation accumulation, preventing inappropriate proliferation, and eliminating or durably restraining cells that have acquired dangerous changes.

Genetic evidence establishes causality. Mice lacking p53 were viable in the reported experimental population but highly susceptible to spontaneous tumours, showing that loss of its normal activity can promote tumorigenesis without requiring a special oncogenic mutant protein.^[ref] The experiment does not establish that p53 has no developmental function in every genetic background. Human inherited TP53 predisposition and recurrent somatic TP53 alterations provide complementary evidence; different missense mutants can lose normal transcriptional function, inhibit remaining wild-type subunits or acquire context-dependent new activities.

To dissect the mechanism, compare matched p53-proficient, deficient and restored cells, then perturb individual targets such as p21 or apoptotic effectors. Measure damage, proliferation, survival and long-term tumour formation separately, because reduced short-term viability is not equivalent to tumour suppression. p53 is a stress-responsive governor of cell fate whose tumour-suppressive value comes from preserving safe proliferation and preventing unsafe clonal expansion.